OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Alldredge on Symptom Management in Ovarian Cancer During PARP Inhibitor Treatment

January 17th 2023

Jill Alldredge, MD, discusses the management of symptoms in patients with ovarian cancer during treatment with a PARP inhibitor.

Dr. Botta on the Diagnosis and Treatment of ESCC

January 17th 2023

Gregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.

Dr. Seetharamu on Individualized Care in SCLC

January 16th 2023

Nagashree Seetharamu, MD, MBBS, discusses interpreting the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and deciding when to initiate hospice care in patients with small cell lung cancer.

Dr. Garcia on Future Expectations of Trials and Therapies in Myelofibrosis

January 16th 2023

Jacqueline S. Garcia, MD, discusses the future expectations of trials and therapies to improve outcomes in myelofibrosis.

Dr. Zhang on the EV-302 Trial in Metastatic Urothelial Cancer

January 16th 2023

Tian Zhang, MD, discusses the investigation of the combination of enfortumab vedotin plus pembrolizumab in the phase 3 EV-302 trial in the frontline setting for metastatic urothelial cancer.

Dr. Jacobs on the Continued Impact of the CAPTIVATE trial in CLL

January 16th 2023

Ryan Jacobs, MD, discusses the implications of next-line treatment strategies following long-term data of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Dreyling on Key Efficacy Results From the TRIANGLE Study in MCL

January 16th 2023

Martin Dreyling, MD, discusses key efficacy results from the phase 3 TRIANGLE study in mantle cell lymphoma.

Dr. Hirsch on Diagnosing and Managing Metastatic SCLC

January 16th 2023

Fred R. Hirsch, MD, PhD, discusses the rarity of diagnosing small cell lung cancer early in the disease course, unmet needs in SCLC screening, the importance of ECOG performance score when considering patients for clinical trials, and factors influencing hospice care decisions in patients with SCLC.

Dr. Pavlick on the Benefit of Neoadjuvant Immunotherapy in Resectable Melanoma

January 16th 2023

Anna C. Pavlick, DO, discusses the potential benefit of neoadjuvant immunotherapy prior to surgical resection, according to results from the phase 2 SWOG S1801 trial.

Dr. Sonbol on Navigating Treatment Selection in Gastroesophageal Cancers

January 16th 2023

Mohamad Bassam Sonbol, MD, discusses key considerations for treatment selection in patients with gastroesophageal junction cancers.

Dr. Dorff on the Exploration of Triplet Combination Therapies in mHSPC

January 12th 2023

Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.

Dr. Dhakal on the Implementation of Trastuzumab Deruxtecan Across the HER2+ Breast Cancer Landscape

January 12th 2023

Ajay Dhakal, MBBS, discusses the evolution and implementation of the antibody-drug conjugate trastuzumab deruxtecan across the landscape of HER2-positive breast cancer landscape.

Dr. Mercado on Evolution of Biopsy Techniques in Lung Cancer

January 12th 2023

Jorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.

Dr. O’Regan on the SOFT Trial in Premenopausal Women With HR+ Breast Cancer

January 12th 2023

Ruth M. O’Regan, MD, discusses the significance of the Breast Cancer Index as a prognostic tool, as well as the investigation of the phase 3 SOFT trial for patients with early-stage, hormone receptor-positive breast cancer.

Dr. Mayer on the PACE Trial in HR+/HER2– Breast Cancer

January 12th 2023

Erica L. Mayer, MD, MPH, discusses findings from the phase 2 PACE trial in patients with hormone receptor (HR)–positive/HER2-negative metastatic breast cancer.

Dr. Jimenez on the Management of Radiation Toxicities in Breast Cancer

January 12th 2023

Rachel Jimenez, MD, discusses the management of toxicities associated with radiotherapy for patients with breast cancer.

Dr. George on the Risk of Cardiotoxicity with Adjuvant T-DM1 Plus Radiotherapy in HER2+ Breast Cancer

January 12th 2023

Mridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.

Dr. Wu on the Current Utility of Targeted Therapy in CRC

January 12th 2023

Christina Wu, MD, discusses key targeted therapies under investigation in patients with colorectal cancer.

Dr. Topp on the Safety Profile of Glofitamab Plus R-CHOP in DLBCL

January 12th 2023

Max S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.

Dr. Allaf on Evaluating the PROSPER-RCC Trial Results in RCC

January 12th 2023

Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.